| Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update |
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published positive data from its global Phase 2 study supporting potential of rademikibart as a novel biologic treatment for patients with asthma and Type 2 inflammation Strong balance sheet with cash runway into 2027 through key clinical catalysts SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today reported financial results for the three months ended March 31, 2025, and provided a business update. “The first quarter of 2025 was very productive, including a positive Type C meeting with the U.S. Food and Drug Administration (FDA), publication of our previously completed global Phase 2 trial results in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), and acceptance of four posters to be presented at the American Thoracic Society (ATS) 2025 International Conference,” said Barry Quart, Pharm.D. |
globenewswire.com |
2025-05-15 13:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD |
– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the initiation of its Phase 2 Seabreeze STAT COPD study (NCT06940154) following written agreement on the final study protocol from the U.S. Food and Drug Administration. The study will evaluate the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in participants with COPD and type 2 inflammation. |
globenewswire.com |
2025-05-14 13:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma |
– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the initiation of its Phase 2 Seabreeze STAT Asthma study (NCT06940141) following written agreement on the final study protocol from the U.S. Food and Drug Administration. The study will evaluate the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in adults and adolescent participants with asthma and type 2 inflammation. |
globenewswire.com |
2025-05-13 13:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference |
– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Advancing rapid clinical development plan for rademikibart; expect to initiate parallel Phase 2 trials in 2Q25 – SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the Company will present four posters at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. The following abstracts are posted on ATS 2025's online itinerary planner for registered users: Title: Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients with Moderate-to-Severe Asthma Presenter: Raúl Collazo, Ph.D. |
globenewswire.com |
2025-04-24 13:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart |
– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Care, in the Office of Immunology and Inflammation. “We are pleased to have the FDA's alignment on our two parallel Phase 2 trials evaluating rademikibart in patients experiencing an acute exacerbation of asthma or COPD, an area where no biologic therapies have been approved or systematically studied,” said Barry Quart, Pharm.D. |
globenewswire.com |
2025-04-01 13:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma |
– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademikibart for 24 weeks, the mean difference from placebo in forced expiratory volume was +420 mL, amongst the largest increases reported for a biologic – SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced the online publication of positive results from the global Phase 2 trial of rademikibart in patients with moderate-to-severe uncontrolled asthma in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). These data highlight rademikibart's potential as a novel biologic treatment option for patients with asthma and Type 2 inflammation, demonstrating rapid onset of action, sustained improvement in forced expiratory volume in one second (FEV1), and clinically important reductions in annual exacerbation rates. |
globenewswire.com |
2025-03-31 20:05:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update |
Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise Unveiled rapid clinical development program for rademikibart initially targeting acute care in asthma and COPD; expect to initiate parallel Phase 2 trials in 2Q 2025 with data expected in 2H 2026 Strong balance sheet with cash runway into 2027 and through key clinical catalysts SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD), today reported financial results for the year ended December 31, 2024, and provided a business update. |
globenewswire.com |
2025-03-31 13:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement |
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD), today announced that it received a letter dated March 24, 2025 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) indicating that, for the last 30 consecutive business days, the bid price for the Company's American Depositary Shares (ADSs) had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). |
globenewswire.com |
2025-03-28 18:05:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma to Present at Two Upcoming Investor Conferences |
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in Asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced that company management will participate in the following upcoming conferences: Leerink Partners Global Biopharma Conference Format: Fireside ChatDate: Wednesday, March 12, 2025Time: 1:40 p.m. ETWebcast Link: Register Here H.C. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Attovia Therapeutics Appoints Chief Financial Officer |
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer |
globenewswire.com |
2024-10-15 11:30:00 |
Czytaj oryginał (ang.) |
| CNTB Stock Surges Over 5% Amid Strong Financial Performance |
Concordia Biotech (CNTB, Financial) saw a significant increase in its stock price, rising by 5.48%. The stock is currently priced at $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%. |
gurufocus.com |
2024-10-02 20:14:57 |
Czytaj oryginał (ang.) |
| Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update |
SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases, today reported financial results for the six months ended June 30, 2024 and provided a business update. |
globenewswire.com |
2024-09-05 20:05:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum |
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA. |
globenewswire.com |
2024-07-01 12:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of Directors (Board), including all of the independent directors of the Board, granted to Barry Quart, Pharm.D., the Company's newly-appointed Chief Executive Officer, and David Szekeres, the Company's newly-appointed President, non-qualified stock option awards to purchase an aggregate of 2,658,734 ordinary shares and 1,772,489 ordinary shares, respectively, under the Connect Biopharma Holdings Limited 2024 Employment Inducement Incentive Award Plan (the Inducement Plan). The options were granted effective June 12, 2024 and have an exercise price of $1.77 per share (the closing price of Connect's ordinary shares on the grant date). The options vest over a period of four years, with 25% vesting on June 12, 2025 and the remaining shares vesting in equal monthly installments thereafter, subject to each executive's continued employment or service. The awards were granted as inducements material to Dr. Quart and Mr. Szekeres entering into employment with Connect in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-06-12 22:03:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces New Leadership and Chair of the Board of Directors |
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board). |
globenewswire.com |
2024-06-12 20:15:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma |
SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA. |
globenewswire.com |
2024-05-22 20:05:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma |
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA. |
globenewswire.com |
2024-05-07 10:30:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update |
SAN DIEGO, CA and TAICANG, China, April 16, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported financial results for the year ended December 31, 2023, and provided a business update. |
globenewswire.com |
2024-04-16 20:05:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference |
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Zheng Wei, Ph.D., Co-Founder and CEO, and Raúl Collazo, Ph.D., Global Head of Medical Affairs will participate in H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference in a fireside chat on Thursday, March 28, 2024 at 4:00 p.m. ET. Please see below for additional details about the event and how to request a one-on-one meeting with management. |
globenewswire.com |
2024-03-19 10:30:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors |
SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors effective immediately. James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company. |
globenewswire.com |
2024-02-12 18:30:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma |
SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma. |
globenewswire.com |
2023-12-12 08:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023 |
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data. The call will feature a discussion with Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting. |
globenewswire.com |
2023-12-11 18:05:00 |
Czytaj oryginał (ang.) |
| Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year? |
Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and DexCom (DXCM) have performed compared to their sector so far this year. |
zacks.com |
2023-11-28 13:17:21 |
Czytaj oryginał (ang.) |
| Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China |
SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that two of its wholly owned subsidiaries, Connect Biopharma Hong Kong Limited and Suzhou Connect Biopharma Co., Ltd., have entered into an exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Ltd. (“Simcere”), to develop and commercialize Connect Biopharma's rademikibart in Greater China. |
globenewswire.com |
2023-11-21 08:03:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis |
SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today positive topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's (formerly known as CBP-201) efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD). These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints. |
globenewswire.com |
2023-11-21 08:00:00 |
Czytaj oryginał (ang.) |
| Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023 |
SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) on Tuesday, November 21, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the trial results. |
globenewswire.com |
2023-11-20 18:41:00 |
Czytaj oryginał (ang.) |
| Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year? |
Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year. |
zacks.com |
2023-11-06 13:18:43 |
Czytaj oryginał (ang.) |
| Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year? |
Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and Haemonetics (HAE) have performed compared to their sector so far this year. |
zacks.com |
2023-10-20 15:18:53 |
Czytaj oryginał (ang.) |
| Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock? |
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2023-09-15 17:32:22 |
Czytaj oryginał (ang.) |